Based on Nobel Prize winning research, SFA Therapeutics is a clinical-stage biopharmaceutical company committed to developing disease-modifying therapies that restore healthy immune system function in patients with cancer, inflammatory and autoimmune disease.​

​​​​

​

​​​

​

​​​​​

Our first-in-class Treg modulators target a fundamental cause of immune dysregulation to restore durable immune homeostasis across autoimmune disorders. We discovered ways to manipulate the structure of endogenous molecules and develop oral delivery formulations, increasing the selectivity and specificity of our small- molecule compounds after elucidating pathways and targets.  ​​​​

 

 

 

​

​We have developed this platform technology by in-depth study of the natural regulators of the immune system present in the gut which allows us to safely target specific diseases and create disease-specific drugs.  

​​​

​Join us on this exciting journey as we work towards a healthier future, one molecule at a time.